natgillin/translations-raw huggingface dataset:
A computer program comprising computer program code to, when loaded into a computer system and executed thereon, cause said computer system to perform all the steps of the method according to any of claims 8 to 14. 
Računalni program, naznačen time što sadrži računalni programski kod koji, kada se učita u računalni sustav 1 tamo izvrši, uzrokuje da navedeni računalni sustav provede sve korake postupka u skladu s bilo kojim od patentnih zahtjeva 8 do 14.
The composition for use of any one of claims 1 to 4, wherein the cancer is selected from the group consisting of bladder cancer, multiple myeloma, brain cancer, pancreatic cancer, plasmacytoma, renal cell carcinoma, prostate cancer, lung cancer, melanoma, breast cancer, mesothelioma, neuroendocrine cancer, ovarian cancer, lymphoma, lymphoid neoplasm, myeloma, leukemia, thyroid cancer, sarcoma, HER2 positive breast cancer, HER2 negative breast cancer, chronic myelogenous leukemia, endometrial cancer, and squamous cell carcinoma of the head and neck. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je rak odabran iz skupine koju čine multipli mijelom, rak gušterače, karcinom bubrežnih stanica, rak prostate, rak pluća, melanom, rak mozga, rak jajnika, limfom, limfoidna neoplazma, mijelom, leukemija, neuroendokrini rak, raka štitnjače, mezoteliom, plazmocitom i sarkom.
In some embodiments related to methods of the present invention, the individual is a mammal. 
U nekim oblicima prikazanog izuma, pojedinac je sisavac.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B1) is azoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
The invention is now described for a home appliance—i.e. 
Izum je opisan za primjenu u domaćinstvu - npr.
The formulation of claim 10 or 11, wherein the intra-granular fraction comprises about 50% of the total weight of the formulation, and wherein the extra-granular fraction comprises about 50% of the total weight of the formulation. 
Formulacija iz zahtjeva 10. ili 11., pri čemu intragranularna frakcija čini 50 % ukupne težine formulacije i pri čemu ekstragranularna frakcija čini 50 % ukupne težine formulacije.
the infection is caused by an organism resistant to tetracycline or any member of first and second generation of tetracycline antibiotics; 
infekcija je uzrokovana organizmom otpornim na tetraciklin ili bilo koji član prve i druge generacije tetraciklinskih antibiotika;
A method of preparing a composition comprising the step of mixing a compound according to any one of claims 1 to 33 and a pharmaceutically acceptable carrier or diluent. 
Postupak proizvodnje sastava, naznačen time, da obuhvaća korak miješanja spoja u skladu s bilo kojim od zahtjeva 1 do 33, s farmaceutski prihvatljivim nosačem ili razrjeđivačem.
An affinity reagent which is capable of specific binding to Lymphocyte antigen 75 for use in treatment or prophylaxis of lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer, lung cancer, colorectal cancer, kidney cancer or liver cancer. 
Antitijelo koje je sposobno za specifično vezivanje limfocitnog antigena 75 za uporabu u liječenju raka pankreasa pri čemu spomenuto antitijelo sadrži ili se konjugira na terapijski dio.
is independently selected from: 
R! je nezavisno odabrano od:
The process of any of claims 13 to 28, wherein the mixture in step c) is refined and decoloured by cation exchange chromatography, anion exchange chromatography, and/or adsorption chromatography. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 10 do 25, naznačen time što se smjesa u koraku c) rafinira i obezboji kationoizmjenjivačkom kromatografijom, anionoizmjenjivačkom kromatografijom i/ili adsorpcijskom kromatografijom.
The pyrazole acid (AY) can be converted to the nitrile (BB) using a similar sequence of steps described for (AC'). 
Pirazol kiselina (AY) se može prevesti u nitril (BB) uporabom sličnog slijeda koraka poput onih opisanih za (AG').
Another aspect of the present invention provides a receiver for processing broadcasting data, the receiver comprising: a QAM demapper configured to demap constellation values corresponding to Layer 1 signaling data into cell words and to multiplex the demapped cell words into Layer 1 signaling data; a bit deinterleaver configured to bit-deinterleave the multiplexed Layer 1 signaling data and at least one LDPC parity bit; a de-puncturing means configured to perform de-puncturing on the LDPC parity bit; an LDPC decoder configured to LDPC-decode the Layer 1 signaling data and the de-punctured LDPC parity bit; and a BCH decoder configured to BCH-decode the LDPC-decoded Layer 1 signaling data and the de-punctured LDPC parity bit, wherein the receiver is configured to process Layer 1 signaling data including Data_Slice_num_PLP information indicating a number of PLPs carried within an associated data slice, the data slice being a group of OFDM cells carrying at least one PLP in a certain frequency sub-band. 
Prijenosnik iz patentnog zahtjeva 1 nadalje obuhvaća: drugi BCH koder konfiguriran za BCH-kodiranje PLP podatka zbog stvaranja podataka zaštićenih od pogreške; drugi LDPC koder konfiguriran za LDPC-kodiranje BCH kodiranih PLP podataka; drugi dio za umetanje bitova konfiguriran za umetanje bitova u LDPC kodirane PLP podatke; drugi QAM maper konfiguriran za demultipleksiranje umetnutih PLP podataka u stanične riječi i za mapiranje staničnih riječi u konstelacijske vrijednosti; 1 dio za umetanje vremena-frekvencije konfiguriran za umetanje vremena-frekvencije u mapirane konstelacijske vrijednosti.
a monocyclic or a bicyclic non-aromatic heterocyclic group 
(1) je monociklička ili biciklička ne-aromatska heterociklička skupina
wherein Hal, R1 and R2 have the same meaning as in formula (IX), and said compound of formula (X) is then reacted with dithiophosphoric acid O,O-diethyl ester or ammonium sulfide to give a compound of formula (XI): 
(X), gdje Hal, R! i R* imaju isto značenje kao u formuli (IX), gdje navedeni spoj formule (X) reagira s 0,0-dietilnim esterom ditiofosforne kiseline ili amonijevim sulfidom kako bi se dobilo spoj formule (XI):
Some embodiments of such compositions are provided by lyophilised formulations which comprise an ecteinascidin such as ET 743 and a disaccharide. 
Neke varijante takvih smjesa dane su kao liofilizirani oblici koji sadrže ekteinascidin kao što je ET 743 i disaharid.
wherein the hanger is pivotally supported from the frame structure such that the hanger and cable tray are pivotable between a deployed position and a stowed positioned. A unit structure for use in forming a modular data center, the unit structure comprising: 
Modularni podatkovni centar prema zahtjevu 8, naznačen time što je vješalica (34, 36) okretno oslonjena s konstrukcije okvira tako da se vješalica i nosač kabela mogu zakretati između raspoređenog položaja 1 spremljenog položaja.
The composition according to claim 11, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 10 do 14, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The process of claim 11, wherein the hydrogenation produces an opioid analgesic composition having an a, B-unsaturated ketone level of less than 25 ppm, less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm. 
Postupak prema zahtjevu 10, naznačen time da hidrogeniranje proizvodi sastav opioidnog analgetika koji ima sadržaj €, B- nezasićenih ketona manji od 25 ppm, manji od 15 ppm, manji od 10 ppm, ili manji od 5 ppm.
A compound of the following formula: and/or a pharmaceutically acceptable salt thereof, in which each of R1, R2, and R5, independently, is H, halo, nitro, amino, cyano, hydroxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkoxy, alkylthio, alkylcarbonyl, carboxy, alkoxycarbonyl, carbonylamino, sulfonylamino, aminocarbonyl, or aminosulfonyl; 
Spoj slijedeće formule: ifili njegova farmaceutski prihvatljiva sol gdje svaki od R,, R», i Rs nezavisno, je H, halo, nitro, amino, cijano, hidroksi, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkoksi, alkiltio, alkilkarbonil, karboksi, alkoksikarbonil, karbonilamino, sulfonilamino, aminokarbonil, ili aminosulfonil; jedan od Rz i Ry je sai
The method according to claim 7, wherein the tissue factor carries the N124A mutation and an hexahistidine tag at the C terminus. 
Metoda u skladu s patentnim zahtjevom 7 pri čemu tkivni faktor nosi N124A mutaciju i heksahistidinski privjesak na C terminusu.
The organic fractions were washed with brine, dried over MgSO4, filtered and evaporated. 
Organske frakcije se isperu s fiziološkom otopinom, osuše preko MgSO,, filtriraju i upare.
a second tank (111) containing preheating liquid fluid and provided with a heater (R), in particular an electric resistor, to heat and maintain the temperature of the hot liquid fluid contained therein, 
drugi spremnik (111) koji sadrži tekućinu za prethodno zagrijavanje i koji ima grijač (R), posebno električni rezistor, za zagrijavanje i održavanje temperature u njemu sadržane tekućine za zagrijavanje,
A is selected from the group consisting of phenyl, naphthyl and heteroaryl; 
A je izabrano iz grupe koju čine fenil, naftil i heteroaril;
"Pharmaceutically acceptable salts, esters, and amides" or "salts, esters, amides, hydrates, and solvates" include carboxylate salts, amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. 
"Farmaceutski prihvatljive soli, esteri i amidi" ili "soli, esteri, amidi, hidrati i solvati" uključuju karboksilatne soli, aminokiselinske adicijske soli, estere i amide koji su unutar razumnog omjera koristi/rizika, farmakološki učinkovite i pogodne za kontaktna tkiva pacijenata bez neželjene toksičnosti, iritacije ili alergijske reakcije.
The T cell of claim 1, wherein the tumor antigen is prostate-specific membrane antigen, CD19, NY-ESO-1, WT-1, hTERT and mesothelin. 
T-stanica za uporabu u liječenju ili prevenciji neoplazije kod subjekta, te T-stanica obuhvaća: kimerni receptor antigena koji veže tumorski antigen; i rekombinantni 4-1 BBL ko-stimulacijski ligand.
Figure 1 shows the arrangement 1 according to a first embodiment as an exploded drawing, namely with the upper part 3 lifted off. 
Slika 1 prikazuje napravu 1 prema prvoj izvedbi u rastavljenom obliku, naime s podignutim gornjim dijelom 3.
the conversion and metabolization, particularly recombinant fermentation, of biomaterial containing L-arabinose, 
- pretvorbi i metaboliziranju, osobito rekombinantnom fermentiranju, biomaterijala koji sadrži L-arabinozu,
a statin selected from rosuvastatin, or a pharmaceutically-acceptable salt or solvate thereof, and atorvastatin, or a pharmaceutically-acceptable salt or solvate thereof. 
statin izabran od rosuvastatina ili njegove farmaceutski prihvatljive soli ili solvata i atorvastatina ili njegove farmaceutski prihvatljive soli ili solvata.
The device as claimed in claim 1, wherein the housing has on the upper end wall a mounting opening for access to the lever mechanism. 
kućište (20) ima na gornjoj strani otvor za montažu (56) za pristup mehanizmu poluge (5.1, 5.2).
said first polypeptide chain comprises an amino terminus and a carboxy terminus and from N-terminus to C-terminus: 
navedeni prvi polipeptidni lanac sadrži amino terminus i karboksi terminus i od N-terminusa do C-terminusa:
The use of a small volume of fluid contributes to the comfort of the procedure for the user. 
Korištenje malog volumena fluida doprinosi udobnosti postupka za korisnicu.
SCH 530348 has the following structure: 
Spoj sljedeće formule:
Further preferred salts are those wherein An+ is Na+, Mg2+ and Ca2+. 
Daljnje prvenstvene soli su one u kojima je A"' = Na', Mg* i Ca".
Accordingly, “in need of treatment” refers to the judgment of the caregiver that the individual is already ill or will become ill and the compounds of the present invention can be used to alleviate, inhibit, ameliorate or prevent the disease, condition or disorder. 
Naravno, "u potrebi za liječenjem" se odnosi na prosudbu onog koji brine za pojedinca, da je isti već bolestan ili će se razboljeti te se stoga spojevi prema prikazanom izumu mogu koristiti da ublaže, inhibiraju, poboljšaju ili spriječe bolest, stanje ili poremećaj.
The device according to any one of the preceding claims, characterized in that the axes (18,3,C,D) of said input and output shafts (19,2) are reciprocally parallel, and in that said freewheels (23,24) comprise respective input members (23a, 24a) operated with opposite rotation directions. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su osi (18, 3, C, D) navedenog ulaznog i izlaznog vratila (19, 2) međusobno paralelne, te da navedeni zamašnjaci (23, 24) imaju odgovarajuće ulazne elemente (23a, 244), koji rade sa suprotnim smjerovima vrtnje.
Contents of the container: 4.5 g 
Datum objave europske prijave patenta:
A drug delivery composition obtainable by the method according to any of the claims 8 to 12. 
Pripravak prema patentnom zahtjevu 8, koji je u obliku spužve.
The mobile station apparatus according to claim 1, wherein DVRBs with consecutive numbers are allocated in the first allocation. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.
After the 3-week rest period of the first cycle, a second induction cycle can begin. 
Nakon 3 tjedna perioda odmora od prvog ciklusa, može početi drugi indukcijski ciklus.
The illuminated microsurgical instrument of any of the preceding claims, wherein the optical fiber has an outer diameter less than 100 microns. 
Osvijetljeni mikrokirurški instrument prema zahtjevu 1, naznačen time, da je optičko vlakno jedno od snopa optičkih vlakana (56) smještenih oko centralnog optičkog vlakna.
At least two brewing chambers are provided, each of the brewing chambers being supplied with heated water from one of the thermoblocks, being adapted to contain a beverage ingredient and being connected with an outlet for draining a brewed beverage. 
Ova naprava također sadržava najmanje dvije komore za kuhanje, gdje se u svaku od komora za kuhanje dovodi zagrijana voda iz jednog od termoblokova, a tako su prilagođene da sadrže sastojak od kojeg se pravi napitak i povezane su s izlazom za ispuštanje kuhanog napitka iz komore za kuhanje.
The base 110 is sized to fit within the recessed well 300 . 
Postolje 110 je takve veličine da odgovara unutar spremnika 300.
The prosthetic valve of claim 1, wherein the struts of the first row are thicker than the struts of the second and third rows. 
Sklop prema patentnom zahtjevu 1, naznačen time što su nosači (20) prvog reda deblji od nosača (24) drugog reda.
A system as claimed in claim 14, wherein the at least one stimulating device and the control device are connected through Internet using a TCP/IP telecommunication standard and the knowledge base where all active credentials are stored and included in the control device is kept secret to the subjects who could receive a stimulation or who could prescribe a treatment. 
16. Sistem kao u patentnim zahtjevima $ i 10, gdje se baza znanja (315) u kojoj su uskladištena sva aktivna odobrenja i koja je uključena u kontrolni uređaj (301) čuva u tajnosti od subjekata koji bi mogli primiti stimulaciju ili koji bi mogli da daju uputstva za tretman.
a) culturing a recombinant host cell comprising a nucleic acid molecule encoding the amino acid backbone of the cyclic peptide of any one of claims 1 to 19 or a vector comprising said nucleic acid molecule under conditions such that the amino acid backbone of the polypeptide of any one of claims 1 to 19 is expressed, and recovering said amino acid backbone; or 
uzgoja rekombinantne stanice-domaćina koja sadrži molekulu nukleinske kiseline koja kodira aminokiselinska okosnica cikličkog peptida u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili vektor koji sadrži navedenu molekulu nukleinske kiseline, u uvjetima koji omogućuju eksprimiranje aminokiselinske okosnice polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 16, te prikupljanje navedene aminokiselinske okosnice; ili
A process for preparing a pharmaceutical product comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof and a pharmaceutically acceptable carrier, wherein the pharmaceutical product has not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition product 5-Chloro- N -ethyl-3-hydroxy-1-methyl-2,4-dioxo- N -phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide, comprising 
Postupak za pripremu farmaceutskog produkta koji sadrži N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid ili njegovu sol, i farmaceutski prihvatljiv nosilac, u čemu farmaceutski produkt nema više od ukupno 0,5 tež.% produkta oksidacijskog raspadanja 5-kloro-N-etil-3-hidroksi-1-metil-2,4-diokso-N-fenil-1,2,3,4-tetrahidro-kinolin-3-karboksamida, u odnosu na N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid, naznačen time, da obuhvaća:
The control meter of claim 1, comprising an electronic circuit (14) for memorizing the activation signal; and a local control unit for reading the activation signal from the electronic circuit and for sequentially resetting the electronic circuit (14) a predetermined number of times and for transmitting a tamper signal to an remote central control and/or interrupting the power supply and/or setting a local flag, if after the predetermined number of reset operations the electronic circuit holds the activation signal. 
Nadzorno brojilo iz najmanje jednog od prethodnih patentnih zahtjeva, naznačeno time, da sadrži elektronički sklop (14) za memoriranje aktivacijskog signala; i lokalnu nadzornu jedinicu za očitavanje aktivacijskog signala iz elektroničkog sklopa i sekvencijalni povrat elektroničkog sklopa u početno stanje (14) određen broj puta i za odašiljanje signala o neovlaštenom baratanju u udaljenu središnju nadzornu jedinicu i/ili prekidanje opskrbe električnom energijom i/ili lokalno označavanje, ako nakon određenog broja operacija povrata na početno stanje elektronički sklop zadržava aktivacijski signal.
information about a prediction mode for a coding unit, and sub-split information about a transformation unit; and a decoding unit which determines a maximum split level of the transformation unit based on the maximum split information for the intra mode when the information about the prediction mode indicates the intra mode, wherein the transformation unit is determined from the coding unit, 
kada informacija o načinu predviđanja upućuje na to da se jedinica za kodiranje predviđa u skladu s intra načinom, određivanje maksimalne razine dijeljenja jedinice transformacije na temelju informacije o maksimalnoj podjeli za jedinicu transformacije s intra načinom;
Respective herbicides are to be selected from four different groups and are to be combined with herbicides to be selected from five other groups. 
Odgovarajući herbicidi se biraju iz četiri različite grupe i kombiniraju se sa herbicidima koji se biraju iz pet drugih grupa.
The use of the inorganic coating according to claim 13 to 15 on a particulate ammonium nitrate-based fertilizer, for reducing caking of an ammonium nitrate-based fertilizer. 
Upotreba anorganskog premaza u skladu s patentnim zahtjevima 13 do 15, naznačen time, da se koristi na praškastom umjetnom gnojivu na bazi amonijeva nitrata, radi smanjenja zgrušavanja gnojiva na bazi amonijeva nitrata.
The pharmaceutical composition of claim 4, wherein the composition contains the corresponding montelukast sulfoxide wherein the corresponding montelukast sulfoxide of in the composition does not increase by more than 1% by weight from the initial amount of montelukast after storage at about 40°C and about 75% relative humidity for 3 months. 
Farmaceutska kompozicija prema patentnom zahtjevu 1, naznačena time što kompozicija sadrži odgovarajući montelukast sulfoksid, pri čemu se odgovarajući montelukast sulfoksid u kompoziciji ne povećava za više od 1 težinski % od početne količine montelukasta poslije čuvanja na oko i oko 75% relativne vlažnosti u trajanju od 3 mjeseca.
The product was used in the following step without further purification. 
Ovaj produkt upotrijebi se u sljedećem koraku, bez daljnjeg pročišćavanja.
The motorized rescue buoy of claim 1, wherein the radio receiver receives control signals for navigating the buoy. 
Motorizirana bova prema zahtjevu 1, naznačena time, da radioupravljač (550) zaprima kontrolne signale za navigaciju bove.
The composition of claim 7 which is suitable for oral or topical administration. 
Oblik doziranja iz patentnog zahtjeva 9 ili patentnog zahtjeva 10, pri čemu je oblik doziranja pogodan za oralnu primjenu.
is hydrogen, halogen, hydroxyl, carboxyl, C1-6alkyl or C3-8cycloalkyl, said C1-6alkyl and C3-8cycloalkyl can optionally be substituted by 1, 2, 3 or 4 substituents independently selected from the group consisting of: halogen, hydroxyl, carboxyl and amino; 
R* je vodik, halogen, hidroksil, karboksil, C,galkil ili Ca gcikloalkil, spomenuti Cigalkil 1 C3gcikloalkil mogu izborno biti supstituirani s 1, 2, 3 ili 4 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, hidroksila, karboksila i amino;
It is another aspect of the invention to provide a nucleic acid molecule encoding at least a binding molecule or functional variant thereof according to the invention. 
Molekula nukleinske kiseline za kodiranje molekule za vezanje, naznačena time, da je sukladna bilo kojem od patentnih zahtjeva 1-3.
As an example, the volatility of RME was assessed both by itself (neat) and as a part of a coating formulation while slowly increasing the temperature (up to 300°C). 
Na primjer, hlapljivi dio RME-a ispitan je u obadva slučaja, u čistom RME-u i kao dio formulacije za premaz, pri čemu je temperatura polako rasla (sve do 300%C).